Clinical Trial Update: A Clinical Study on the Efficacy and Safety of the Combination of Limertinib and Bevacizumab Versus Limertinib as First-line Treatment for NSCLC. [Phase 2]

View source ↗

Summary

Phase 2 clinical trial evaluating limertinib plus bevacizumab versus limertinib as first-line treatment for EGFR-mutant, PD-L1 positive advanced non-small cell …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• Bevacizumab (bevacizumab)
• Limertinib (Limertinib)

Snippet

Sponsor: Shanghai Chest Hospital | Conditions: EGFR Mutation Positive Advanced Non Small Cell Lung Cancer, PD-L1 Positive | Phase 2 | Status: NOT_YET_RECRUITING